D-2570 treatment for active systemic lupus erythematosus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 2 trial assigns eligible adults with active SLE to one of three D-2570 dose groups or to placebo and follows them for 48 weeks of once-daily dosing. Participants must have had SLE for at least 24 weeks, a SLEDAI-2K score of ≥8, and be on stable background therapy before randomization. Investigators and participants remain blinded throughout treatment, with scheduled pharmacokinetic and pharmacodynamic blood sampling and routine safety assessments. After completing treatment subjects enter a safety follow-up period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient voluntarily participates in this study after full informed consent.
* The age is 18 years ≤ age ≤ 70 years, regardless of gender.
* Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.
* SLEDAI-2K total score ≥ 8.
* On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.

Exclusion Criteria:

* History of infection as defined in the protocol.
* Any of the medical diseases or disorders listed in the protocol.
* Significant, uncontrolled or unstable disease in any organ.

Where it's running

• Linfen Central Hospital
  Linfen, Jiangxi, China Recruiting

Study contacts

• Principal investigator: Xiaofeng — Zeng
• Study coordinator: Hang Ren, Master
• Email: hang.ren@inventisbio.com
• Phone: 86+15900699091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing D-2570 in adults with varying kidney function

  This study tests a single dose of D-2570 in adults aged 18–70 with different levels of kidney function to see how the drug behaves in the body.

  Recruiting Phase 1 InventisBio Co., Ltd · Hefei, Anhui · NCT07715175

• Pharmacokinetics of D-2570 in people with liver impairment and in healthy volunteers

  This study tests how D-2570 moves through and affects the body in adults with liver impairment compared to those with normal liver function.

  Recruiting Phase 1 InventisBio Co., Ltd · Bengbu, Anhui · NCT07715149

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• D-2570 in Moderate to Severe Plaque Psoriasis

  This study tests whether D-2570 can safely improve symptoms in adults with moderate to severe plaque psoriasis.

  Recruiting at 3 sites Phase 2 InventisBio Co., Ltd · Birmingham, Alabama and 19 other locations · NCT07489885

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

• D-2570 treatment for people with active psoriatic arthritis (Phase II)

  This Phase II trial tests whether the investigational medicine D-2570 helps adults with active psoriatic arthritis reduce joint pain and swelling compared with placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Chengdu, Sichuan · NCT07315061

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.